Related Experiment Video
Updated: Sep 29, 2025
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of
Tereza Altschmiedová1, Veronika Todorovová2, Michaela Šnejdrlová2
1Center of Preventive Cardiology, 3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Tereza.Altschmiedova@vfn.cz.
Purpose Of Review:
PCSK9 inhibitors have been shown to be the most effective class of drugs modifying the levels of LDL-cholesterol as the main risk factor for atherosclerotic cardiovascular disease. The aim of this paper is to assess the effect of monoclonal antibodies on lipid and lipoprotein metabolism in real-world practice.
Recent Findings:
The outcome trials showed effective reduction of LDL-C by 56-62%. Landmark studies enrolling over a total of 46,000 patients with CHD in their medical history demonstrated the beneficial effect of both agents on cardiovascular morbidity and mortality. The data from real everyday clinical practice are very limited or missing. Even in real-world practice, PCSK9 inhibitors have been shown to be an effective, safe, and well-tolerated class of drugs with effects comparable with those reported from large randomized controlled trials.
Insights
Monoclonal antibodies targeting PCSK9 effectively lower LDL-cholesterol in real-world settings, mirroring outcomes from clinical trials. These PCSK9 inhibitors demonstrate safety and tolerability, supporting their use in managing atherosclerotic cardiovascular disease risk.
Area of Science:
- Cardiology
- Pharmacology
- Lipid Metabolism
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are highly effective in reducing LDL-cholesterol.
- Elevated LDL-cholesterol is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
- Real-world data on PCSK9 inhibitor effectiveness and safety are limited.
Purpose of the Study:
- To evaluate the impact of PCSK9 inhibitors on lipid and lipoprotein metabolism in routine clinical practice.
- To assess the real-world effectiveness and tolerability of monoclonal antibodies targeting PCSK9.
Main Methods:
- Review of clinical data from real-world practice settings.
- Analysis of lipid profiles and patient outcomes associated with PCSK9 inhibitor use.
- Comparison of real-world findings with results from landmark randomized controlled trials.
Main Results:
- PCSK9 inhibitors demonstrated significant LDL-cholesterol reduction (56-62%) in outcome trials.
- Real-world data indicate comparable effectiveness, safety, and tolerability to trial results.
- Monoclonal antibodies targeting PCSK9 are effective in managing lipid metabolism in diverse patient populations.
Conclusions:
- PCSK9 inhibitors are a safe, effective, and well-tolerated therapeutic option in real-world practice.
- These agents provide substantial cardiovascular risk reduction comparable to large clinical trials.
- Further real-world studies are warranted to fully elucidate the long-term benefits of PCSK9 inhibitors.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...